Brain Cancer Trial, Recruiting NCT07144735 Sponsor: Peking University Third Hospital Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT07144735
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 70 years old (inclusive), of any sex
  • People who have at least one tumour area that can be assessed, with a confirmed diagnosis of glioblastoma (a type of brain tumour classified as WHO Grade IV), and scan results suggesting the tumour has continued to grow or come back after treatment
  • People whose physical functioning is rated at 60% or above on a standard medical scale that measures ability to carry out daily activities (called the Karnofsky Performance Status)
  • People whose life expectancy is estimated to be more than 4 weeks
  • People who finished radiation therapy or other cancer treatments (such as temozolomide, bevacizumab, or similar medicines) at least 4 weeks before joining, and whose side effects from those treatments have mostly resolved to a mild level or lower (with the exception of things like hair loss)
  • People who are able to undergo an MRI scan with contrast dye
  • People whose blood test results show that the liver, kidneys, bone marrow, and blood clotting are all working within acceptable ranges (confirm specific values with the trial site)
  • People with no known significant inherited (hereditary) diseases
  • People whose heart is functioning normally, with a pumping efficiency measurement above 55%
  • People with no bleeding or blood clotting disorders
  • People with no signs of active bacterial, fungal, or viral infection in the blood, and no signs of brain/spinal fluid infection (meningitis), within 48 hours before receiving the trial treatment
  • Women who are able to become pregnant must have a negative pregnancy test within 7 days before starting treatment, and must agree to use contraception during the trial and for 6 months after the last treatment session; any suspected pregnancy during the trial must be reported to the treating doctor immediately
  • People who have read, understood, and signed a written consent form agreeing to take part

Who may not be able to join:

  • People with an active hepatitis B or C infection, HIV, or any other untreated active infection
  • People who are pregnant or currently breastfeeding
  • People with organ failure
  • People with a long-term (chronic) condition that requires ongoing treatment with immune-suppressing or hormonal medicines
  • People with a known allergy to immunotherapy or related cell-based treatments
  • People with a serious ongoing illness that is not well controlled
  • People with a psychiatric condition or personal circumstances that may make it difficult to follow the trial requirements
  • People who have previously had an organ transplant or who are currently waiting for one

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (+86)-135-1108-7060

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University Third Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Adverse Events (AEs); Incidence of Dose-Limiting Toxicities (DLTs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov